Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Notes underwriting agrmnt
Histogen Inc. (CNAT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
10/04/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
09/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/15/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Histogen to Explore Strategic Alternatives SAN DIEGO, July 5, 2023 – Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital Partners, LLC, to act as a strategic advisor in this process. Potential strategic alternatives that may be explored or evaluated as part of this process ..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Histogen Reports First Quarter 2023 Results and Provides Business Update Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement with Johns Hopkins University Steven J. Mento Ph.D. Appointed President and CEO SAN DIEGO, May 11, 2023 – Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the first quarter ended March 31, 2023, and provided an updat..."
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/28/2023 4/A Reyes Joyce (See Remarks) has filed a Form 4 on Histogen Inc.
Txns: Granted 47,417 options to buy @ $0.95, valued at $45k
Granted 16,659 options to buy @ $0.95, valued at $15.8k
Disposed/sold 1,200 options to buy @ $0
Disposed/sold 4,452 options to buy @ $0
Disposed/sold 7,833 options to buy @ $0
04/03/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 3, 2023 – Histogen Inc. , a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that the company has signed an exclusive license agreement with Johns Hopkins University. The intellectual property associated with this license covers the use of emricasan for the treatment of disease in humans re..."
03/14/2023 4 Reyes Joyce (See Remarks) has filed a Form 4 on Histogen Inc.
Txns: Granted 47,417 options to buy @ $0.95, valued at $45k
Granted 16,659 options to buy @ $0.95, valued at $15.8k
Disposed/sold 1,200 options to buy @ $0
Disposed/sold 7,833 options to buy @ $0
03/14/2023 4 Knudson Susan A. (COO and CFO) has filed a Form 4 on Histogen Inc.
Txns: Granted 79,027 options to buy @ $0.95, valued at $75.1k
Granted 27,766 options to buy @ $0.95, valued at $26.4k
Disposed/sold 6,206 options to buy @ $0
Disposed/sold 5,600 options to buy @ $0
Disposed/sold 8,490 options to buy @ $0
03/14/2023 4 Mento Steven J (President and CEO) has filed a Form 4 on Histogen Inc.
Txns: Granted 158,055 options to buy @ $0.95, valued at $150.2k
Granted 55,532 options to buy @ $0.95, valued at $52.8k
Disposed/sold 18,892 options to buy @ $0
Disposed/sold 7,582 options to buy @ $0
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Histogen Reports Year-End 2022 Results and Provides Business Update Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 9, 2023 – Histogen Inc. , a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. “Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections , includ..."
02/27/2023 4 Spada Alfred P. (See Remarks) has filed a Form 4 on Histogen Inc.
Txns: Granted 106,793 options to buy @ $1.041, valued at $111.2k
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 5% stake in Histogen Inc.
02/08/2023 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 5.3% stake in Histogen Inc.
02/03/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
01/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT is entered into as of February 1, 2023 , by and between Histogen Inc., a Delaware corporation , and Alfred P. Spada Ph.D. . RECITALS WHEREAS, Employer wishes to engage Executive as Executive Vice President and Chief Scientific Officer on the terms and conditions hereinafter set forth. AGREEMENT NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements set forth herein, Executive and Employer agree as follows: 1. Employment Term. The term of this Agreement shall commence on the Effective Date and will continue until terminated as provided in Section 7 below. 2. Scope of Employment. a. Position and Duties. Executive shall serve as Company’s CSO. Executive agrees that during the Employme...",
"Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, January 3, 2023 -- Histogen Inc. , a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. “We are very excited about Dr. Spada joining our management team. Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors,” sa..."
12/02/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update SAN DIEGO, Nov. 10, 2022 – Histogen Inc. , a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. “We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus and evaluating our caspase-1 inhibitors that impact the inflammasome pathway,” s..."
11/09/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/09/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
08/04/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/03/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/28/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/12/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy